Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 29-Aug-22 8:30 AM View:  | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 26-Aug-22 | Market Purchase | 50,000 | $0.45 | $22,500.00 | 349% 14.34K to 64.34K | (11%) |
| 10-Jun-22 4:46 PM View: | Shetty Ajit Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 43% 1.57K to 2.24K | |
| 10-Jun-22 4:47 PM View: | Fischer Seth H.Z. Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 48% 1.4K to 2.07K | |
| 10-Jun-22 4:45 PM View: | Tursi James Patrick Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 48% 1.4K to 2.07K | |
| 10-Jun-22 4:49 PM View: | Barbari Sharon Surrey Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 52% 1.28K to 1.95K | |
| 10-Jun-22 4:48 PM View: | Carson Sandra Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 52% 1.28K to 1.95K | |
| 10-Jun-22 4:45 PM View: | Torrente Josephine Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 34% 1.99K to 2.66K | |
| 10-Jun-22 4:47 PM View: | Hubbard John W Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-22 | Grant | 670 | -- | -- | 48% 1.4K to 2.07K | |
| 15-Oct-21 4:05 PM View: | Perceptive Advisors LLC 10% Owner | Agile Therapeutics, Inc. (AGRX) | 13-Oct-21 | Market Purchase | 5,734,560 | $0.85 | $4,874,380.00 | 36% 15.92M to 21.65M | (10%) |
| 14-Oct-21 8:01 AM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 13-Oct-21 | Purchase | 58,824 | -- | -- | 23% 251.31K to 310.13K | |
| 14-Oct-21 8:00 AM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 13-Oct-21 | Purchase | 58,824 | -- | -- | 11% 514.91K to 573.73K | |
| 08-Oct-21 5:03 PM View: | Torrente Josephine Director | Agile Therapeutics, Inc. (AGRX) | 07-Oct-21 | Grant | 79,593 | -- | -- | 100% 0 to 79.59K | |
| 29-Jul-21 7:52 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 29-Jul-21 | Market Purchase | 26,200 | $1.26 | $33,095.80 | 5% 488.71K to 514.91K | (41%) |
| 28-Jul-21 8:57 PM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 27-Jul-21 | Market Purchase | 50,000 | $1.08 | $54,145.00 | 25% 201.31K to 251.31K | (31%) |
| 10-Jun-21 7:08 PM View: | Tursi James Patrick Director | Agile Therapeutics, Inc. (AGRX) | 08-Jun-21 | Grant | 24,510 | -- | -- | 78% 31.34K to 55.85K | |
| 10-Jun-21 7:11 PM View: | Barbari Sharon Surrey Director | Agile Therapeutics, Inc. (AGRX) | 08-Jun-21 | Grant | 24,510 | -- | -- | 92% 26.79K to 51.3K | |
| 11-Jun-21 5:55 PM View: | Carson Sandra Director | Agile Therapeutics, Inc. (AGRX) | 08-Jun-21 | Grant | 24,510 | -- | -- | 92% 26.79K to 51.3K | |
| 10-Jun-21 7:12 PM View: | Hubbard John W Director | Agile Therapeutics, Inc. (AGRX) | 08-Jun-21 | Grant | 24,510 | -- | -- | 78% 31.34K to 55.85K | |
| 10-Jun-21 7:10 PM View: | Shetty Ajit Director | Agile Therapeutics, Inc. (AGRX) | 08-Jun-21 | Grant | 24,510 | -- | -- | 64% 38.34K to 62.85K | |
| 10-Jun-21 7:13 PM View: | Fischer Seth H.Z. Director | Agile Therapeutics, Inc. (AGRX) | 08-Jun-21 | Grant | 24,510 | -- | -- | 78% 31.34K to 55.85K | |
| 19-May-21 8:30 AM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 18-May-21 | Market Purchase | 20,000 | $1.61 | $32,200.00 | 4% 468.71K to 488.71K | (54%) |
| 12-May-21 4:31 PM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 11-May-21 | Market Purchase | 20,000 | $1.35 | $27,000.00 | 11% 181.31K to 201.31K | (45%) |
| 30-Mar-21 4:48 PM View: | Butch Jason Principal Accounting Officer | Agile Therapeutics, Inc. (AGRX) | 29-Mar-21 | Market Purchase | 1,358 | $1.99 | $2,702.42 | 7% 18.64K to 20.0K | (62%) |
| 30-Mar-21 4:48 PM View: | Butch Jason Principal Accounting Officer | Agile Therapeutics, Inc. (AGRX) | 26-Mar-21 | Market Purchase | 8,642 | $2.01 | $17,370.40 | 86% 10.0K to 18.64K | (63%) |
| 23-Mar-21 5:23 PM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 23-Mar-21 | Market Purchase | 50,000 | $2.05 | $102,500.00 | 38% 131.31K to 181.31K | (63%) |
| 23-Mar-21 5:24 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 23-Mar-21 | Market Purchase | 12,500 | $2.00 | $25,030.00 | 3% 456.21K to 468.71K | (63%) |
| 28-Jan-21 6:34 PM View: | Conway Robert G SVP Chief Supply Chain Officer | Agile Therapeutics, Inc. (AGRX) | 27-Jan-21 | Grant | 35,461 | -- | -- | 155% 22.9K to 58.36K | |
| 23-Nov-20 5:00 PM View: | Conway Robert G SVP Chief Supply Chain Officer | Agile Therapeutics, Inc. (AGRX) | 19-Nov-20 | Option Exercise | 4,149 | $1.76 | $7,302.24 | 22% 18.75K to 22.9K | |
| 28-Sep-20 4:10 PM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 28-Sep-20 | Market Purchase | 9,000 | $2.85 | $25,650.00 | 7% 122.31K to 131.31K | (74%) |
| 26-Aug-20 5:00 PM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 26-Aug-20 | Grant | 37,500 | $1.01 | $37,875.00 | 44% 84.81K to 122.31K | |
| 20-Aug-20 4:15 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 20-Aug-20 | Option Exercise | 94,599 | $1.76 | $166,494.00 | 26% 361.61K to 456.21K | |
| 23-Jun-20 5:00 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 22-Jun-20 | Option Exercise | 50,000 | $1.76 | $88,000.00 | 16% 311.61K to 361.61K | |
| 11-Jun-20 5:20 PM View: | Barbari Sharon Surrey Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-20 | Grant | 26,786 | -- | -- | 100% 0 to 26.79K | |
| 11-Jun-20 5:21 PM View: | Carson Sandra Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-20 | Grant | 26,786 | -- | -- | 100% 0 to 26.79K | |
| 11-Jun-20 5:22 PM View: | Fischer Seth H.Z. Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-20 | Grant | 13,393 | -- | -- | 75% 17.95K to 31.34K | |
| 11-Jun-20 5:22 PM View: | Tursi James Patrick Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-20 | Grant | 13,393 | -- | -- | 75% 17.95K to 31.34K | |
| 11-Jun-20 5:21 PM View: | Shetty Ajit Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-20 | Grant | 13,393 | -- | -- | 54% 24.95K to 38.34K | |
| 11-Jun-20 5:21 PM View: | Hubbard John W Director | Agile Therapeutics, Inc. (AGRX) | 09-Jun-20 | Grant | 13,393 | -- | -- | 75% 17.95K to 31.34K | |
| 16-Mar-20 4:30 PM View: | Gilmore Geoffrey General Counsel | Agile Therapeutics, Inc. (AGRX) | 13-Mar-20 | Grant | 25,500 | $1.56 | $39,780.00 | 46% 55.78K to 81.28K | (52%) |
| 17-Mar-20 3:50 PM View: | Perceptive Advisors LLC 10% Owner | Agile Therapeutics, Inc. (AGRX) | 13-Mar-20 | Market Purchase | 1,000,000 | $1.75 | $1,750,000.00 | 7% 14.92M to 15.92M | (57%) |
| 06-Mar-20 8:00 AM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 04-Mar-20 | Market Purchase | 50,000 | $2.32 | $116,000.00 | 510% 9.81K to 59.81K | (68%) |
| 06-Mar-20 8:00 AM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 04-Mar-20 | Market Purchase | 25,000 | $2.35 | $58,750.00 | 42% 59.81K to 84.81K | (68%) |
| 27-Feb-20 9:27 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 27-Feb-20 | Market Purchase | 10,000 | $2.71 | $27,100.00 | 3% 301.61K to 311.61K | (72%) |
| 27-Feb-20 9:27 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 27-Feb-20 | Option Exercise | 16,541 | $0.71 | $11,744.10 | 6% 285.07K to 301.61K | |
| 25-Feb-20 8:10 PM View: | Perceptive Advisors LLC 10% Owner | Agile Therapeutics, Inc. (AGRX) | 25-Feb-20 | Market Purchase | 3,000,000 | $3.00 | $9,000,000.00 | 25% 11.92M to 14.92M | (75%) |
| 24-Jan-20 7:59 PM View: | Reilly Dennis Chief Financial Officer | Agile Therapeutics, Inc. (AGRX) | 22-Jan-20 | Grant | 9,806 | -- | -- | 100% 0 to 9.81K | |
| 24-Jan-20 7:59 PM View: | Altomari Alfred Chief Executive Officer Director | Agile Therapeutics, Inc. (AGRX) | 22-Jan-20 | Grant | 26,502 | -- | -- | 10% 258.57K to 285.07K | |
| 24-Jan-20 7:59 PM View: | Conway Robert G Sr. VP Manufacturing & Supply | Agile Therapeutics, Inc. (AGRX) | 22-Jan-20 | Grant | 6,272 | -- | -- | 100% 6.28K to 12.55K | |
| 24-Jan-20 8:00 PM View: | Gilmore Geoffrey General Counsel | Agile Therapeutics, Inc. (AGRX) | 22-Jan-20 | Grant | 10,071 | -- | -- | 22% 45.71K to 55.78K | |
| 18-Nov-19 7:00 PM View: | Perceptive Advisors LLC 10% Owner | Agile Therapeutics, Inc. (AGRX) | 15-Nov-19 | Market Purchase | 5,333,800 | $1.68 | $8,940,810.00 | 81% 6.59M to 11.92M | (55%) |
